Debu Tripathy

Debu Tripathy, MD is Professor and Chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. He is a nationally recognized leader in the clinical and translational management of metastatic breast cancer, with particular expertise in CDK4/6 inhibitor-based therapy for hormone receptor-positive (HR+) disease. Dr. Tripathy has contributed to pivotal trials evaluating palbociclib, ribociclib, and abemaciclib across multiple lines of therapy in HR+/HER2- metastatic breast cancer, and has been a key investigator in elucidating mechanisms of resistance to both CDK4/6 inhibitors and endocrine agents including aromatase inhibitors and fulvestrant. His translational work spans liquid biopsy approaches for ESR1 and RB1 mutation tracking, gene expression profiling to predict endocrine sensitivity, and combination strategies to overcome acquired resistance. Dr. Tripathy is a past president of the San Antonio Breast Cancer Symposium and has served on the editorial boards of the Journal of Clinical Oncology and npj Breast Cancer. He has authored or co-authored more than 250 peer-reviewed publications and is an active contributor to ASCO and NCCN breast cancer guidelines. Under his leadership, MD Anderson's breast medical oncology department has consistently ranked among the top clinical and research programs in the world.